Study Complete
Sponsor ID
20080615
AMG 853 Phase 2 Study in Subjects with Inadequately Controlled Asthma
Study Details
The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) composite symptoms scores from baseline to week 12.
Protocol Summary
Primary Outcome Measures
The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) composite symptoms scores from baseline to week 12.
Timeframe: Baseline to Week 12
Secondary Outcome Measures
Evaluate the efficacy of AMG 853 as measured by use of rescue short-acting β-agonist (SABA)
Timeframe: Baseline to Week 12
Evaluate the efficacy of AMG 853 as measured by daily symptom score (aggregate/night and individual symptoms; and symptom free days)
Timeframe: Baseline to Week 12
Evaluate the efficacy of AMG 853 as measured by pre- and post-bronchodilator forced expiratory volume in 1 second (FEV1)
Timeframe: Baseline to Week 12
Evaluate the efficacy of AMG 853 as measured by AM and PM peak expiratory flow rate (PEFR)
Timeframe: Baseline to Week 12
Evaluate the efficacy of AMG 853 as measured by asthma quality of life questionnaire (AQLQ)
Timeframe: Baseline to Week 12
Study Documents
Study Synopsis
Available Language(s): English
Locations
No locations found.